SAN RAMON, Calif.--(BUSINESS WIRE)--BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced that Ralph Stephan von Bardeleben, MD, of the University Medical Center of Mainz (Germany) has joined the European REVIVE-HF clinical trial of the Revivent TC™ Transcatheter Ventricular Enhancement System as co-principal investigator.
Inward Displacement Approach Assesses HFrEF Patients for Left Ventricular Device Therapy
MANSFIELD, MA, USA – March 15, 2023 – BioVentrix®, Inc., a privately held medical device company developing less invasive therapies to directly treat the dilated left ventricle leading to progressive heart failure, today announced the publication of a peer-reviewed paper in the Journal of Clinical Medicine, titled, Inward Displacement, A Novel Approach to Measuring Left Ventricular (LV) Function in Patients with HFrEF after Undergoing BioVentrix Therapy.